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ABSTRACT
Risankizumab, an interleukin (IL)-23 antago-
nist, is a highly effective treatment for moderate
to severe psoriasis. Crusted scabies (CS) is a rare
and severe form of scabies, occurring mainly in
immunosuppressed patients and/or neurologi-
cally or mentally ill patients. A young girl with
Down syndrome was diagnosed with a hyperk-
eratotic form of psoriasis. As treatment with
topical dermocorticosteroids, UVB-photother-
apy and acitretin for 6 weeks did not improve
the lesions, two injections of risankizumab were
administered. Following these injections, the
lesions became rapidly even more severely
crusted, and new lesions appeared on the
extremities and the face of the patient. There
was histological evidence of a high charge of
scabies, leading to a diagnosis of CS. The patient
was hospitalized and successfully treated by
local permethrine and systemic ivermectine.
This case suggests that even though anti-IL23
antagonists display an excellent overall safety
profile, a particular caution for infections
should still be respected in patients with
underlying risk factors.
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Crusted scabies is a rare disease affecting
mainly fragile patients.
The immune response against crusted
scabies requires T-helper (Th)2 and Th17
cells.
Practitioners should consider crusted
scabies when confronted with
hyperkeratotic and scaly nail or skin
lesions with or without pruritus.
Crusted scabies is a complication of
biotherapies, affecting directly or
indirectly the interleukin (IL)-17 pathway.
Anti-IL23 and anti-IL17 antagonists
should be used with caution in patients
with Down syndrome.
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INTRODUCTION
Crusted scabies (CS) or hyperkeratotic scabies is
rather exceptional and poorly known to general
practitioners and even to dermatologists [1]. Its
rarity and clinical heterogeneity make the
diagnosis difficult [2]. Risk factors for CS are
immunocompromised patients in general and/
or individuals suffering from neurologically or
mentally debilitating diseases [1–4]. Patients
with Down syndrome are even at higher risk to
develop CS as they present immune alterations
altering their anti-infectious defense lines [5].
Classes of immunosuppressive drugs constitut-
ing a specific risk factor for CS are not clearly
established. Cases of CS during biotherapies
have only been rarely reported in the literature.
A young patient with Down syndrome with
scabies, misdiagnosed and treated as psoriasis,
presented a severe aggravation and extension of
the scabies infestation resulting in CS following
unjustified injections of risankizumab, an anti-
interleukin (IL)-23 antagonist.
This case report was written after receiving
oral and written consent from the patient and
patient’s mother, and was compliant with the
University Hospital ethical guidelines. Written
informed consent was also obtained from the
patient and the patient’s mother for the publi-
cation of the patient’s clinical pictures.
CASE PRESENTATION
A 26-year-old woman with Down syndrome
presented at the Emergency Department with a
severe inflammatory and ichthyosiform der-
matosis affecting her face and extremities
(Fig. 1).
The patient lives alone with her mother and
was not attending any specialized institution.
She had been consulting a dermatologist for 2
years for psoriasis-like lesions. Initially her
hands presented various degrees of hyperker-
atosis and pachyonychia on the nails; however,
progressively hyperkeratotic ichthyosis-like
lesions appeared on the fingers and the limbs.
These lesions were non-pruritic and no scratch
lesions were identified. She had never
previously presented any dermatological prob-
lems and had a completely normal skin. Her
mother had a longstanding history of psoriasis
limited to the elbows. The clinical aspects and
the genetic history orientated to a diagnosis of
psoriasis. The patient was initially treated with
clobetasol propionate 0.05% ointment (once
daily) for several weeks, without any clinical
improvement, then treated with betamethasone
combined with calcipotriol ointment (once
daily) for several weeks. As this last topical
treatment did not improve the patient’s lesions,
it was decided to use UVB-phototherapy (3
times per week for a total of 30 sessions) while
continuing the use of topical steroids with
creams containing 10% urea. There were still no
clinical improvements, so the topical dermo-
corticosteroids were stopped and oral acitretin
(20 mg/day) was administered for 8 weeks in
combination with a keratolytic cream (10%
urea) (once daily). Again, there was no clinical
improvement of the lesions, leading the der-
matologist to switch to a biotherapy. Two
injections of risankizumab were administered
with a 15-day interval between injections. In
the weeks following the last injection, the
patient’s skin condition deteriorated progres-
sively, and new profuse crusted lesions appeared
on previously non-involved skin areas,
prompting the visit to the Emergency Depart-
ment. At admission, the entire tegument was
hyperkeratotic with an ichtyosiform appear-
ance, with an important involvement of the
scalp and the extension regions of the limbs.
She also had multiple and painful skin fissures
in the flexural areas (Fig. 1). There were no sys-
temic signs or no fever, and lymphadenopathies
were not identified. A skin biopsy was per-
formed and revealed an epidermal infiltration
of a large number of Sarcoptes scabiei, leading to
a final diagnosis of CS (Fig. 2). A blood sample
revealed hyperleukocytosis (14.000/mm3) with
a predominant increase of neutrophils (86%) as
well as a severe inflammatory syndrome (C-re-
active protein 124 mg/L), probably linked to a
bacterial superinfection of the fissured lesions.
Her mother also presented signs of pruritic
scabies infestation at presentation as well did an
uncle living in the same house. The origin of
the infestation was unclear, particularly as the
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patient did not attend any institution. Due to
the severity of the dermatosis and the Down
syndrome the patient was hospitalized. The
anti-parasitic treatment scheme was based on
the published recommendations for CS [6]. A
tube of 30 g of permethrin (50 mg/gr) cream was
applied in the evening for 8 h, from day 1 to
(and including) day 7, with a repetition of the
application twice a week for a duration of
4 weeks. The local treatment was combined
with ivermectin tablets (0.2 mg/kg) on days 1, 2,
8, 9, 15, 22 and 29. The patient also received
supportive pain medication (paracetamol 4
9 500 mg/day when needed) and local kera-
tolytic care (urea cream 15%, 1–2/day). After 1
week of hospitalization, the patient’s inflam-
matory syndrome regressed rapidly and her skin
condition improved progressively. One month
after discharge there were no signs of recurrent
disease (Fig. 3).
DISCUSSION
Crusted scabies or hyperkeratotic scabies is a
rare variant of Sarcoptes scabies var. hominis
infestation [1]. In such infestations, the mites
colonize the stratum corneum by the thousands
[4, 7]. CS preferentially develops in individuals
with cellular immunity deficiency (organ
transplant recipients, bone marrow recipients,
persons with human immunodeficiency virus
[HIV], lymphomas, etc…) and debilitated indi-
viduals (dementia, Down syndrome, quad-
riplegic, etc…) [1–5]. Debilitation or the
inability to scratch may furthermore lead to an
uncontrollable proliferation of the parasites
Fig. 1 Severe hyperkeratotic, crusted, scaling and fissuring crusted scabies of the hands (a), lower extremities (b) and face
(c) at admission
Fig. 2 High load of scabies in the skin biopsy. es
Triangular needles, ee scabies exosqueleton. Asterisk indi-
cates hyperkeratosis, yellow arrow denotes eggs, blue arrow
denote the epidermis
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[1, 2, 5]. Several studies identified a T-helper
(Th)1/Th2-cell imbalance with a deficiency in
the Th2 response in CS [8]. In classical scabies,
the parasitic proliferation is controlled by both
cellular and humoral immunity. In CS, there is
no control of the parasitic proliferation despite
high levels of immunoglobulins E and blood
hypereosinophilia [2]. Skin biopsies of CS
patients have revealed an absence of B lym-
phocytes or specific antibodies but a large
quantity of T lymphocytes (T cells) with a high
CD8?/CD4? ratio [7], suggesting an important
role of CD8? T cells against CS. This ratio is
reversed in cases of classic scabies, for which the
count for CD4? T-cells is fourfold higher than
that for CD8? T-cells [7]. The precise role of the
cytotoxic T cells in CS is not yet clear. They may
have a direct effect on the keratinocytes and
may partially explain the inflammatory
response.
The clinical manifestations of CS are highly
polymorphous, with the most common being
diffuse, thickened squamous-crusted lesions
with palmoplantar hyperkeratosis and nail
deformities [1]. Unlike classic scabies, pruritus is
not always a symptom [3, 4]. The usual loca-
tions are the extremities and scalp, but the
disease can spread over the entire skin [3, 4]. A
frequent complication is a bacterial infection of
the skin cracks [2, 3]. Psoriasis is a common
misdiagnosis, particularly in the absence of itch
[2, 4, 7].
In addition to their various anatomical and
physiological alterations, patients with Down
syndrome present modifications of their innate
and adaptive immunity with a moderate lym-
phopenia, impaired T-cell proliferation,
impaired neutrophil chemotaxis and a poor
humoral response, resulting in an increase in
the frequency and severity of infections and
autoimmune and hematological pathologies
[9]. CS is not uncommon in individuals with
Down syndrome, although the exact mecha-
nisms for the increased propensity are still not
fully known [5]. It is possible that the mental
deficit of these patients also contributes to CS
due to an altered interpretation of itching if
present [5, 9]. In addition, patients with Down
syndrome often live in institutions with other
debilitated residents, which are typical envi-
ronments favoring scabies epidemics [7].
CS is also observed in kidney transplant and
HIV-positive patients [10]. More recently, a
dozen cases of CS have been described in
Fig. 3 Aspect of the face (a), hands (b) and lower limbs (c) 1 month after hospitalization
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patients using anti-tumor necrosis factor alpha
therapies; including etanercept [11], adali-
mumab [6, 12] and infliximab [13]. One case
was described in a patient on ipilimumab, an
anti-T-cell CTLA-4 antibody, for the treatment
of melanoma [14]. IL-23 leads to downstream
IL-17 and IL-22 production, inducing
chemokines that will attract neutrophils and
macrophages to the infested sites [15]. Indeed,
very high levels of IL-17 have been measured in
the skin of CS patients [16]. Therefore, by
blocking IL-23, risankizumab decreases the
activation of Th17 cells and the production of
IL-17 [17], decreasing the activation of the
chemotaxic and stimulatory system of neu-
trophils and macrophages, an important
defense line against CS. The long-term use of
topical corticosteroids probably maintained the
scabies infection, but no aggravation nor
extension, indicative of CS, was ever observed.
Furthermore, as the use of topical corticosteri-
oids as interrupted at least 2 months before the
injections, it seems more likely that the trans-
formation of scabies into CS was linked to the
injections rather than to any other drug the
patient had used.
CONCLUSION
In conclusion, the Down syndrome initially
facilitated the scabies infestation. Chronicity
was probably linked to the longstanding use of
topical corticosteroids. Finally, the risankizu-
mab-linked IL-23 and downstream IL-17 block-
ade transformed the scabies infestation into
severe CS. Specific caution should be paid for
infections when using biologicals affecting
directly or indirectly the IL-17 pathway in
patients with Down syndrome.
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